Nishigandha D. Naikawadi, Mayuri C. More, Prakash D. Jadhav, Sanket J. Kapse, Vivekkumar Redasani
Nishigandha D. Naikawadi*, Mayuri C. More, Prakash D. Jadhav, Sanket J. Kapse, Vivekkumar Redasani
YSPM’s YTC Faculty of Pharmacy Wadhe, Satara – 415011.
Volume - 15,
Issue - 4,
Year - 2023
To investigate the many bacteriocidal properties of chaulmoogra oil, which are used to treat leprosy and TB. Chaulmoogric acid, an antibacterial substance, is the main active component of chaulmoogra oil. The common name Chaulmoogra is used to refer to the tree Hydnocarpus kurzii, which belongs to the Flacourtiaceae family. Thailand, Myanmar, and India are the native countries of this tree. The two main Indian states where this tree can be found are Assam and Tripura. The ripe seeds of plants like Taraktogenos kurzii King, also called Hydnocarpus kurzii (King) Warb., Hydnocarpus wightiana Blume, Hydnocarpus anthelminticta Pierre, Hydnocarpus heterophylla, and other species of Hydnocarpus that are members of the Flacourtiaceae family are used to make the fixed oil known as chaulmoogra. Chaulmoogra oil has powerful bactericidal effect against the bacteria that cause leprosy and tuberculosis because it contains unsaturated fatty acids. Leprosy, TB, gout, and skin disorders have all been treated with it for millennia in Ayurveda.
Cite this article:
Nishigandha D. Naikawadi, Mayuri C. More, Prakash D. Jadhav, Sanket J. Kapse, Vivekkumar Redasani. A Review on Formulation Development using Chaulmoogra Oil. Research Journal of Pharmacognosy and Phytochemistry. 2023; 15(4):311-8. doi: 10.52711/0975-4385.2023.00049
Nishigandha D. Naikawadi, Mayuri C. More, Prakash D. Jadhav, Sanket J. Kapse, Vivekkumar Redasani. A Review on Formulation Development using Chaulmoogra Oil. Research Journal of Pharmacognosy and Phytochemistry. 2023; 15(4):311-8. doi: 10.52711/0975-4385.2023.00049 Available on: https://rjpponline.org/AbstractView.aspx?PID=2023-15-4-8
1. Arch Dermat et al. This article discusses the use of Chaulmoogra oil's fatty acids in the treatment of leprosy and other diseases. 1922; 5 (1): 94-101.
2. Chauhan Lalita and Shalini Gupta. Creams: A Review on Classification and Preparation approaches, evaluation, and use. Pharmaceutical and Medication Delivery Journal. 2020; 281-289
3. Manas Rajan Sahoo, SP Dhanabal, and others. A review of the pharmacological, phytochemical, and ethanopharmacological effects of Hydnocarpus. 2014; 154(1): 17-25
4. Chemical and therapeutic potential of chaulmoogra oil, K.B. Ramesh Kumar et al. 2011.
5. Komal Patel et al. Extraction Technique Review. 2019; 7-11
6. L. Lev. It also comprises the activity of hydnocarpic and Chaulmoogra acid as well as the crude sodium salts of the fatty acids from Chaulmoogra oil. 1975.
7. Ninth, Norton, SA. Plant resources for dermatological. I. Chaulmoogra and Hydnocarpus. Dermatology. 1994.
8. Chaulmoogra oil for the treatment of leprosy. Parascandola. J. History of Pharmacy. 45 (2): 47–57.
9. Hisham Abdulkhader and Rameshkumar Koranappalili. Chemistry and medicinal potential of chaulmoogra oil. 2011: 339-356:
10. K.R. Ranganathan and T.R. Seshadri. Hydnocarpus wightiana seed hulls were used to make the isohydnocarpin composition. Indian Journal of Chemistry. 1974; 12: 993.
11. Sengupta A., J. K. Gupta, J. Dutta, and A. Ghosh. The fatty acids found in chaulmoogra oil. Journal of the Science of Food and Agriculture. 1973; 24(6): 669-674.
12. Rajitha, P. Shammika et al. Topical nanoemulsion made of chaulmoogra oil and methotrexate for the treatment of psoriasis. Panonnummal Journal of Drug Delivery Science and Technology. 2019; 49: 463-476
13. H.H. Roenigk, R. Auerbach, H.I. Maibach, G.D. Weinstein. Methotrexate in psoriasis, Revised guidelines. J. Am. Acad. Dermatol. 1988; 19: 145–156.
14. M.E. Weinblatt, J.S. Coblyn, D.A. Fox, P.A. Fraser, D.E. Holdsworth, D.N. Glass, D. E. Trentham. Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl.J. Med. 1985; 312: 818–822.
15. S. Herman, N. Zurgil, M. Deutsch. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm. Res. 2005; 54 : 273–280.
16. E.W. Jeffes, J.L. McCullough, M.R. Pittelkow, A. McCormick, J. Almanzor, G. Liu,M. Dang, K. Voss, J. Voss, A. Schlotzhauer. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J. Invest. Dermatol. 1995; 104:183–188.
17. N. Hornung, T. Ellingsen, K. Stengaard-Pedersen, J.H. Poulsen. Folate, homo cysteine, and cobalamin status in patients with rheumatoid arthritis treated withmethotrexate, and the effect of low dose folic acid supplement. J. Rheumatol. 2004; 31: 2374–2381.
18. A.E. van Ede, R.F. Laan, H.J. Blom, G.H. Boers, C.J. Haagsma, C.M. Thomas, T.M. De Boo, L.B. van de Putte. Homocysteine and folate status in methotrexatetreated patients with rheumatoid arthritis. Rheumatology. 2002; 41: 658–665.
19. B. Rama, A. Shantha. Optimization of methotrexate transdermal patches: effect of variables on in vitro, ex vivo permeation and flux. Int. J. Phar. Sci. Lett. 2012; 21: 53–59.
20. P. Rachna, K. Veena, A. Sneh, K.K. Rope. Transdermal iontophoretic delivery of methotrexate: physicochemical considerations. Trends Biomater. Artif. Organs. 2005; 18: 187–190.
21. P. Srisuk, P. Thongnopnua, U. Raktanonchai, S. Kanokpanont. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro trans epidermal delivery targeting psoriasis treatment. Int. J.Pharm. 2012; 427: 426–434.
22. L. Yin-Ku, H. Zih-Rou, Z. Rou-Zi, F. Jia-You. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int. J. Nanomed.2010; 5 : 117–128.
23. P.K. Lakshmi, G.S. Devi, S. Bhaskaran, S. Sacchidanand. Niosomal methotrexate gel in the treatment of psoriasis phasi I and phase II studies. Indian J. Dermatol.Venereol. Leprol. 2007; 73 : 157–161.
24. A. Saleh, M. Abuhilal, B. Cheung, Methotrexate in psoriasis. From A to Z, J. Turk.Acad. Dermatol. 2010; 4: 401–410.
25. R.N. Gursoy, S. Benita. Self emulsifying drug delivery systems (SEDDS) for Improved Oral delivery of lipophilic drugs. Biomed. Pharmacother. 2004; 58 : 173–182.
26. S. Shafiq, F. Shakeel, S. Talegaonkar, J. Ali, S. Baboota, A. Ahuja, R.K. Khar, M. Ali. Formulation development and optimization using nanoemulsion technique: a technical note. AAPS PharmSciTech. 2007; 8: E12–E17.
27. Tamilvanan, S. Benita. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur. J. Pharm. Biopharm. 2004; 58 : 357–368.
28. S. Baboota, F. Shakeel, A. Ahuja, J. Ali, S. Shafiq. Design development and evaluation of novel nanoemulsion formulation for transdermal potential of celecoxib. Acta Pharm. 2007; 57: 315–332.
29. H. Ichikawa, T. Watanabe, H. Tokumitsu, Y. Fukumori. Formulation considerations of gadolinium lipid nanoemulsion for intravenous delivery to tumors in neutron capture therapy. Curr. Drug Deliv. 2007; 4: 131–240.
30. S.\ Shafiq, F. Shakeel, R.K. Khar, Enhanced stability of ramipril in nanoemulsion containing Cremophor-EL: a technical note. AAPS Pharm Sci Tech. 2008; 9:1097–1101.
31. F.S. dos Santos, L.P. de Souza, A.C. Siani. Chaulmoogra oil as scientific knowledge: the construction of a treatment for leprosy. Hist. Cienc. Saude Manguinhos. 2004; 15: 29–47.
32. J. Parascandola. Chaulmoogra oil and the treatment of leprosy, Pharm. Hist. 2003; 45: 47–57.
33. Yehwanth Shenoy. Biological Diversity Act 2002: India's lost decade. JTFP. 2013; 1:73–77.
34. D.K. Sharma, I. H. Hall. Hypolipidemic, anti-inflammatory, anti-neoplastic and cytotoxicityofflavanolignans isolated from Hydnocarpus wightiana seeds. J. Nat.
35. Rajitha, P. Shammika et al. Topical nanoemulsion made of chaulmoogra oil and methotrexate for the treatment of psoriasis. Panonnummal Journal of Drug Delivery Science and Technology. 2019; 49: 463-476